Instruction for use: Panthenol 100 mg Jenapharm

Active substance Dexpanthenol

ATX code D03AX03Dexpanthenol

Pharmacological group

Vitamins and vitamin-like remedies

dermotropic means

Regenerants and reparants

Nosological classification (ICD-10)

J00 Acute nasopharyngitis [runny nose]

Viral rhinitis, Inflammation of the nasopharynx, Inflammatory diseases of the nose, purulent rhinitis, Nasal congestion, Nasal congestion with colds and flu, The difficulty of nasal breathing, The difficulty of nasal breathing for colds, Difficulty in nasal breathing, Difficulty in nasal breathing in colds, nasal, hypersecretion, cold, ARI with rhinitis phenomena, coryza, Acute rhinitis of various origins, Acute rhinitis with thick purulent mucous exudate, Acute nasopharyngitis, Swelling of the mucosa of the nasopharynx, Rhinitis, rhinorrhea, Infectious-inflammatory diseases of ENT organs, heavy cold, rhinopharyngitis, nasopharyngitis

J02.9 Acute pharyngitis, unspecified

purulent pharyngitis, Acute nasopharyngitis,Limfonodulyarny pharyngitis

J04 Acute laryngitis and tracheitis

Cough in diseases of the upper respiratory tract, Laryngitis, acute Laryngitis, tracheitis sharp, pharyngolaryngitis, Infectious-inflammatory diseases of ENT organs

J40 Bronchitis, not specified as acute or chronic

wheeze bronchitis, Allergic bronchitis, Bronchitis asthma, Rinotraheobronhit, Asthmatic bronchitis, Bacterial bronchitis, Bronchitis, Bronchitis smoker, Inflammation of the lower respiratory tract, bronchi disease, Qatar smoker, smokers Cough, Cough in inflammatory diseases of the lung and bronchus, Violation of bronchial secretions, Violation of the functions of the bronchi, Acute bronchitis, Subacute bronchitis, tracheobronchitis, Chronic lung disease

L58 Radiation dermatitis radiation

Radiation injury of the skin, Radiation skin lesions, Radiation damage to the skin and mucous membranes, Skin lesion with radiation therapy, Irritation after exposure to X-rays, Radiation damage to the skin, Radio-epileleitis, Radiation acute syndrome

L87 Transepidermal perforations

L89 Decubital ulcer

Decubital gangrene, Bedsores, Bedsore, Secondary-infected bedsores, Gangrene decubital

R23.4 Skin structure changes

Cracks in the skin, Erosion, Postpone, Decreased skin elasticity, Violation of keratinization processes, Age-related skin changes, Cracks in the skin, Increased dryness of the skin

T14.0 Surface injury of unspecified body region

Abrasions, Scratch, Skin Wounds, Wounds of soft tissues, Hematoma, Hematoma of traumatic origin, Hematomas, Hematomas of muscles, Hematomas of soft tissues, Healing of the skin, Bruise, Bruising due to sprains and bruises, Microtrauma, External bruises, Small combing, Superficial hematoma, Superficial damage to the skin and mucous membranes, Subcutaneous hematoma, Post-traumatic hematoma, Post-traumatic disturbance of microcirculation, Skinness of the skin, Traumatic plexus lesions, Injury, Contusion of soft tissues, Joint bruise, Traumatic bruises, Traumatic injury, Primary treatment of surface contaminated wounds, Abrasion, Bruise

T30 Thermal and chemical burns, unspecified

Pain syndrome with burns, Pain in burns, Pain with burns, Sluggishly healing post-burn wounds, Deep burns with a wet scab, Deep burns with abundant compartments, Deep burn, Laser burn, Burn, Burn of rectum and perineum, Burn with mild exudation, Burn disease, Burn injury, Superficial burn, Superficial burn of I and II degree, Superficial skin burns, After-burn trophic ulcer and wound, Post-burn complication, Loss of fluid in burns, Sepsis burn, Thermal burns, Thermal skin lesions, Thermal burn, Trophic after-burn ulcers, Chemical burn, Surgical burn

Composition and form of release

1 tablet contains dexpanthenol 100 mg; in the package of 20 pcs.

1 ampoule with 2 ml solution for injection - 500 mg; in the package 10 pcs.

pharmachologic effect

Replenishment of pantothenic acid deficiency.

Indications

Tablets: inflammatory diseases of the upper respiratory tract (bronchitis, pharyngitis, laryngitis, tracheitis, rhinitis), condition after tonsillectomy, stomatitis. Solution for injection: prevention and treatment of postoperative intestinal atony, paralytic intestinal obstruction; parenterally or inward: insufficiency of pantothenic acid (sensation of tingling, numbness, pain in the toes and in the feet).

Contraindications

Hemophilia, mechanical intestinal obstruction (for parenteral administration).

Side effects

Allergic reactions (with parenteral administration).

Dosing and Administration

Inside (the tablets are kept in the mouth until completely absorbed). Adults with diseases of the mucosa - 200-400 mg per day at regular intervals; with pantothenic acid deficiency - 100 mg, regardless of food intake, with a small amount of liquid (not more than 500 mg per day).

subcutaneously, intramuscularly, intravenously. For the prevention of postoperative intestinal atony - 4 ml at or soon after surgery (IV); treatment of postoperative intestinal atony - 4 ml (if necessary, injections can be repeated after 6 hours) iv or IM; with paralytic obstruction of the intestine - 2 ml IM or IV injection - then 2 and after 6 hours before the normalization of the intestine.

Precautionary measures

It should be prescribed with caution in chronic kidney failure.

Storage conditions

In the dark place.

Keep out of the reach of children.

Shelf life

3 years.

Do not use after the expiry date printed on the package.